Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cep 701
2. Cep-701
3. Cep701
4. Kt-555
5. Kt-5555
6. Kt5555
7. Sp-924
8. Sp924
9. Spm-924
1. 111358-88-4
2. Cep-701
3. Kt-5555
4. Spm-924
5. Kt5555
6. Cep 701
7. Sp924
8. Sp 924
9. Sp-924
10. Kt 5555
11. Kt-555
12. Cep701
13. C26h21n3o4
14. Chembl603469
15. Do989gc5d1
16. A-154475.0
17. (9s,10s,12r)-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one
18. Ncgc00168772-01
19. (5s,6s,8r)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5h-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6h)-one
20. A-154475
21. Lestaurtinib [usan]
22. Lestaurtinib (usan/inn)
23. Lestaurtinib [usan:inn]
24. Unii-do989gc5d1
25. 4otg
26. A 1544750
27. Cep-701 Hydrate
28. Lestaurtinib; Cep701
29. Lestaurtinib [inn]
30. Dsstox_cid_26778
31. Dsstox_rid_81897
32. Dsstox_gsid_46778
33. Lestaurtinib [mart.]
34. Lestaurtinib [who-dd]
35. A 154475.0
36. Gtpl5672
37. Schembl1649693
38. Dtxsid5046778
39. Chebi:91471
40. 9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s,10s,12r)-
41. 9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s,10s,12r)-
42. Bcp06977
43. Zinc3781738
44. Tox21_112633
45. Bdbm50308060
46. Mfcd09840836
47. Nsc772196
48. Nsc800782
49. Akos024457603
50. Ac-5243
51. Am81228
52. Db06469
53. Nsc-772196
54. Nsc-800782
55. Ncgc00168772-02
56. Ncgc00168772-03
57. Ncgc00168772-04
58. Hy-50867
59. Cas-111358-88-4
60. Cs-0004336
61. D04696
62. J-002567
63. Q6531771
64. Brd-k23192422-001-01-1
65. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaen-3-one
66. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaen-3-one
67. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
68. (9s,10s,12r)-10-hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one
69. (9s,10s,12r)-2,3,9,10,11,12-hexahyd Ro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epo Xy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1, 6]benzodiazocin-1-one
70. 16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one
71. 9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s-(9alpha,10beta,12alpha))-
| Molecular Weight | 439.5 g/mol |
|---|---|
| Molecular Formula | C26H21N3O4 |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 439.15320616 g/mol |
| Monoisotopic Mass | 439.15320616 g/mol |
| Topological Polar Surface Area | 88.6 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 886 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).
Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.
ABOUT THIS PAGE
A Lestaurtinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lestaurtinib, including repackagers and relabelers. The FDA regulates Lestaurtinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lestaurtinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lestaurtinib supplier is an individual or a company that provides Lestaurtinib active pharmaceutical ingredient (API) or Lestaurtinib finished formulations upon request. The Lestaurtinib suppliers may include Lestaurtinib API manufacturers, exporters, distributors and traders.
click here to find a list of Lestaurtinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lestaurtinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Lestaurtinib active pharmaceutical ingredient (API) in detail. Different forms of Lestaurtinib DMFs exist exist since differing nations have different regulations, such as Lestaurtinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lestaurtinib DMF submitted to regulatory agencies in the US is known as a USDMF. Lestaurtinib USDMF includes data on Lestaurtinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lestaurtinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lestaurtinib suppliers with USDMF on PharmaCompass.
Lestaurtinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lestaurtinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lestaurtinib GMP manufacturer or Lestaurtinib GMP API supplier for your needs.
A Lestaurtinib CoA (Certificate of Analysis) is a formal document that attests to Lestaurtinib's compliance with Lestaurtinib specifications and serves as a tool for batch-level quality control.
Lestaurtinib CoA mostly includes findings from lab analyses of a specific batch. For each Lestaurtinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lestaurtinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lestaurtinib EP), Lestaurtinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lestaurtinib USP).
LOOKING FOR A SUPPLIER?
